Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
Issued Date
2022-01-01
Resource Type
ISSN
17451981
eISSN
17404398
Scopus ID
2-s2.0-85151561640
Journal Title
Drugs in Context
Volume
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
Drugs in Context Vol.11 (2022)
Suggested Citation
Tran N.T., Sutcharitchan P., Janprasit J., Rojnuckarin P., Morales N.P., Luechapudiporn R. Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE. Drugs in Context Vol.11 (2022). doi:10.7573/dic.2022-7-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86888
Title
Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
Other Contributor(s)
Abstract
Background: Hyperfunctional platelets play important roles in thromboembolism in patients with β-thalassaemia/ haemoglobin E (β-thal/HbE). Our previous study revealed ex vivo inhibitory effects of deferiprone on normal platelets. Herein, we aimed to investigate the in vivo effects on platelets in patients with β-thal/HbE. Methods: A prospective, self-controlled clinical study on 30 patients with β-thal/HbE who had received therapeutic deferiprone (20.8–94.5 mg/kg/day) was conducted. The study included a 4-week washout period followed by 4 and 12 weeks of deferiprone treatment. Platelet aggregation was performed by a turbidimetric method. Levels of deferiprone and soluble platelet (sP)-selectin in serum were measured by high-performance liquid chromatography (HPLC) and enzyme-linked immunosorbent assay (ELISA) kit, respectively. Results: The washout period significantly enhanced platelet hyperactivity both in patients who had undergone splenectomy and in those who had not. At 2 hours following the administration of a single dose of deferiprone, platelet sensitivity to ADP and arachidonic acid was significantly reduced. The inhibitory effects of deferiprone were gradually increased over the period of 4 and 12 weeks. Deferiprone also depressed sP-selectin levels, but the effect was stable over longer follow-up periods. Correlation analysis demonstrated the relationship between serum levels of deferiprone, sP-selectin, and platelet activities induced by ADP and arachidonic acid. Conclusion: We first demonstrated the in vivo antiplatelet effect and benefit of short-term treatment of deferiprone in patients with β-thal/HbE. The impact on thrombotic outcomes deserves further study.